Management of CLL patients early in the COVID ‐19 pandemic: An international survey of CLL experts-Reference-Cited by-同舟云学术

Management of CLL patients early in the COVID ‐19 pandemic: An international survey of CLL experts

Published:2020-05-13 Issue:8 Volume:95 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Koffman Brian¹,Mato Anthony²^ORCID,Byrd John C.³,Danilov Alexey⁴,Hedrick Brad¹,Ujjani Chaitra⁵,Roeker Lindsey²,Stephens Deborah M.⁶,Davids Matthew S.⁷,Pagel John M.⁸,Shadman Mazyar⁵^ORCID

Affiliation:

1. CLL Society Claremont California USA

2. Memorial Sloan Kettering Cancer Center New York New York USA

3. The Ohio State University Comprehensive Cancer CenterJames Cancer Hospital and Solove Research Institute Columbus Ohio USA

4. City of Hope National Medical Center Duarte California USA

5. Fred Hutchinson Cancer Research Center and University of Washington Seattle Washington USA

6. Huntsman Cancer Institute at the University of Utah Salt Lake City Utah USA

7. Dana‐Farber/Brigham and Womenʼs Cancer Center Boston Massachusetts USA

8. Swedish Cancer Institute Seattle Washington USA

Funder

National Institutes of Health

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25851

Reference6 articles.

1. Covid-19: risk factors for severe disease and death

2. Immune defects in patients with chronic lymphocytic leukemia

3. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

4. Ibrutinib treatment improves T cell number and function in CLL patients

5. Btk Regulates Macrophage Polarization in Response to Lipopolysaccharide

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case report of prolonged viral shedding of SARS-CoV-2 in a patient who receive ibrutinib for CLL therapy;BMC Infectious Diseases;2024-09-02

2. A case report of prolonged viral shedding of SARS-CoV-2 in a patient who receive ibrutinib for CLL therapy;2023-11-21

3. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL;Blood Advances;2023-11-15

4. Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL);Expert Review of Pharmacoeconomics & Outcomes Research;2023-04-11

5. The worldwide impact of COVID-19 on cancer care: A meta-analysis of surveys published after the first wave of the pandemic;Frontiers in Oncology;2022-09-29